What we do

Leveraging medical images to support personalized therapies.

Quantitative imaging plays a key role for personalized medicine. It enables more accurate diagnosis and drug efficacy measurement, while providing the potential to predict clinical evolution and drug efficacy for disease-changing therapies.

Qynapse innovates in this area by delivering a unique technology for biomarkers analysis and monitoring.


QyScore® is a cloud-based software for the automated extraction, quantification and comparison to normative dataset of imaging markers of central nervous system (CNS) diseases.

    • Imaging features:

    • Brain white matter lesion load
    • Grey and white matter volumes
    • Hippocampal volume
    • Amygdala volume
    • Basal ganglia volume
    • Thalamic volume
    • Cerebellar volume
    • Spinal cord volume
    • Clinical applications:

    • Multiple sclerosis
    • Alzheimer's disease
    • Parkinson's disease
    • Epilepsy
    • Stroke
    • Bipolar disorder
    • Post-traumatic stress disorder

QyScore® is fully automated, providing reliable results in a few minutes, either through an intuitive user interface or a clinical report. Individual analysis is presented in comparison with a normative dataset of healthy subjects, to support decision-making in both clinical trials and clinical routine.

  • Global and local atrophies
  • Lesion load

Clinical trials

Qynapse delivers precise, fast and reliable data analyses, leading to the best therapies assessments through the most relevant imaging endpoints and the most accurate selection of patients, for more targeted and successful clinical trials.

Our team provides the following services for effective clinical trials planning and management:

Ultimately, the implementation of standardized imaging protocols along with QyScore® automated quantification reduces inter and intra-rater variability inherent to the visual analysis of MRI data.

Clinical routine

Clinical benefit

  • In the clinical routine, QyScore® provides automated, reliable and reproducible measurements of brain structures from MR image to support:

    • Differential diagnosis
    • Measurement of clinical progression
    • Measurement of drug efficacy
    • Monitoring of drug adverse effects

    Results are presented in comparison to normative data for a given time point and across time for the same patient.

A cloud-based platform

QyScore® can be fully integrated into routine clinical practice through leading RIS/PACS systems, and can be operated with any MRI scan from 1.5T and 3T scanners.

About us

Qynapse is a medical technology company, spin-off of the renowned CATI consortium of neuroimaging research laboratories.
Headquartered in Paris, Qynapse provides a cloud-based solution for pharmaceutical companies and healthcare providers to support the diagnosis, prognosis and drug efficacy measurement for central nervous system diseases (such as dementia, multiple sclerosis, Parkinson’s and ischemic stroke).
Qynapse is ISO 13485:2016-certified.

Management team

  • Olivier Courrèges
  • Clarisse Longo dos Santos, PhD
    VP Clinical Operations
  • Jean-Baptiste Martini
    R&D Leader, Imaging
  • Antoine Movschin
    R&D Leader, Data Science


We have developed strategic partnerships to deliver state of the art technology and services for imaging biomarkers analysis and monitoring. Our key technology partners and sponsors include:



Grants and awards:


Optimal measures. Optimized therapies.
Our mission at Qynapse is to transform the development and clinical management of innovative therapies for central nervous system diseases.
Leveraging cutting-edge image analysis and machine learning technology with unmatched clinical expertise, we develop and commercialize medical devices software that help diagnose, predict clinical evolution and measure drug efficacy in an unprecedented way.
We are looking for exceptional talents who are ready to make a difference.
Here are our current job openings:
Don't hesitate to contact us at careers[@]qynapse.com if our current open positions do not match your profile.